Wednesday, November 18, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 56

EU approves Rasonque for previously treated metastatic pancreatic cancer

The European Commission has cleared Rasonque, an oral non-chemotherapy drug, for adults with metastatic pancreatic adenocarcinoma who have already had at least one line of systemic therapy. The approval applies across the EU plus Iceland, Norway and Liechtenstein, and covers patients with or without a RAS mutation. Revolution Medicines says it is now working with European health systems to open access.

By the Paparazzi desk November 18, 2026 · 5:00 AM · rarecancernews.com · 2 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: rarecancernews.com.
  • The source published it on Nov 18, 2026 at 5:00 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The European Commission approved Rasonque (daraxonrasib) as a monotherapy for metastatic PDAC in patients who have received at least one prior line of systemic therapy. The decision covers all EU member states, plus Iceland, Norway and Liechtenstein, and applies to patients with or without an identified RAS tumor mutation. Revolution Medicines, the drug's maker, announced the clearance in a company press release.

The green light lands a few months after Rasonque won a similar U.S. approval. Revolution CEO Mark A. Goldsmith called the European decision a pivotal moment for people in the EU with metastatic pancreatic cancer and their families. He said the company is working with healthcare systems and stakeholders across the region to support timely access for eligible patients, according to the release.

Sponsored

Regulators based the approvals mainly on data from RASolute 302, a Phase 3 trial that tested Rasonque against standard chemotherapy in 500 adults with previously treated metastatic PDAC. Rasonque produced a median overall survival time of 13.2 months, versus 6.7 months for chemotherapy. The drug works by blocking RAS proteins, a group of signaling proteins that commonly contribute to abnormal cell growth in PDAC.

Common side effects listed in the U.S. prescribing information include rash, diarrhea, nausea, fatigue, vomiting, abdominal pain and swelling. Stomatitis, reduced appetite and hemorrhage also showed up commonly. Thomas Seufferlein, medical director at Ulm University Hospital in Germany, called the approval an important advance for patients with this aggressive and difficult-to-treat cancer, and said physicians have long had limited options beyond chemotherapy.

Revolution is now testing Rasonque as a potential first-line treatment in RASolute 303, an ongoing Phase 3 trial enrolling adults with newly diagnosed PDAC across Europe, Asia, Australia, Canada and Brazil. Participants are randomly assigned to Rasonque alone, Rasonque plus standard chemotherapy, or chemotherapy alone. The trial's main goal is to determine whether Rasonque slows disease progression and improves survival.

TopicsRasonque · daraxonrasib · Revolution Medicines · European Commission · Mark A. Goldsmith · Thomas Seufferlein · RASolute 302 · RASolute 303

Share

Source: rarecancernews.com

Written by AI from verified reporting.

More stories

  • Health & science 18:16 UTC · 36 minutes ago · theguardian.com · 0 views
    E coli toxin colibactin flagged to MPs as prime suspect in under-50 bowel cancer rise
  • Health & science 16:53 UTC · 2 hours ago · medicalxpress.com · Caught by @breakwater128 · 2 views
    Five-Day Antiviral Infusion Safe for Long COVID, ERASE Trial Finds
  • Health & science 15:47 UTC · 3 hours ago · dailycoffeenews.com · 2 views
    FDA Pullplug on Methylene Chloride Use, Decaf Ban Fight Continues
  • Health & science 15:31 UTC · 3 hours ago · wam.ae · 2 views
    UAE drug regulator: no medical ads without approval, influencer promos banned
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.